So I do believe that endocrine therapy is the key backbone to work with the neoadjuvant setting. We’ve been seeing that the four months that we did in this trial, maybe it’s too short. So for future trials, I would advise anyone that it’s developing, and we are considering this in our team also, to go with at least six months of neoadjuvant endocrine therapy...
So I do believe that endocrine therapy is the key backbone to work with the neoadjuvant setting. We’ve been seeing that the four months that we did in this trial, maybe it’s too short. So for future trials, I would advise anyone that it’s developing, and we are considering this in our team also, to go with at least six months of neoadjuvant endocrine therapy. That would be one of the key points and one of the key messages for the future. The other lesson learned is that endocrine therapy alone doesn’t seem to work, so we’re trying to find the best partners. We have seen several attempts here when we saw the ROS1 inhibition. Let’s see what Jason Mouabbi can do in the advanced setting with the REPLOT study.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
